Comment on “EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation” - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Commentary on the EHA Guidelines for Chronic Lymphocytic Leukemia and Richter Transformation Management

  • By

  • Alessandra Tedeschi

  • Raul Cordoba

  • Alessandra Ferrajoli

  • George Follows

  • Anna Maria Frustaci

  • Anne Sophie Michallet

  • Talha Munir

  • Susan O'Brien

  • John F. Seymour

  • Tait Shanafelt

  • Clemens Martin Wendtner

  • Pier Luigi Zinzani

  • Stephan Stilgenbauer

  • October 13, 2026

Share

  • 1

    The EHA guidelines provide comprehensive CLL and Richter transformation recommendations, but their evidence base includes heterogeneous trials and real-world data amid limited mature head-to-head stud

  • 2

    The commentary argues that some first-line recommendations lack high-level evidence, including preferring fixed-duration therapy without TP53 aberrations and avoiding continuous therapy in patients wi

  • 3

    Continuous therapy remains effective in mutated-IGHV CLL, and the commentary cautions against treating fixed-duration therapy as categorically superior or continuous therapy as inappropriate.

  • 4

    The commentary cautions that MCBS:H scores depend on trial design and context and should not be interpreted as treatment recommendations or definitive subgroup evidence.

  • 5

    The guidelines emphasize TP53 and IGHV status and integrate clinical and logistical factors, but the commentary identifies limited guidance on frailty and treatment evidence in older, comorbid patient

Original Source(s)

Comment on “EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation”

  • by Alessandra Tedeschi, Raul Cordoba, Alessandra Ferrajoli, George Follows, Anna Maria Frustaci, Anne Sophie Michallet, Talha Munir, Susan O'Brien, John F. Seymour, Tait Shanafelt, Clemens Martin Wendtner, Pier Luigi Zinzani, Stephan Stilgenbauer

  • October 13, 2026

Related Content

Precision Treatment, Earlier Molecular Detection and De-escalation Transforming Breast Cancer Care

Breast cancer management is becoming increasingly biology-driven, with treatment decisions extending well beyond anatomic stage and conventional receptor classification.

  • by

  • October 14, 2026

  • 6 min
Musings From the Power List: Jason Bock

Jason Bock shares his outlook on RNA-targeting therapies, personalized medicine, and the future of drug development

2026 ASCO Breast Cancer Highlights: SENOMAC

Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.

  • October 15, 2026

  • 1 min